Showing results (11-20 of 71) with videos related to
Sort By:
Pageof 8
Applied Health Economics and Health Policy|March 31, 2026
Agreement in Qualitative and Quantitative Assessments of Disease Severity: Evidence from Pharmaceutical Reimbursement in SwedenMartin Henriksson, Lars Sandman, Jonathan SiverskogBMJ Public Health|June 29, 2026
Long-term outcomes of a digital alcohol intervention targeting online help-seekers: a simulation study of incidence of disease, quality-adjusted life-years and costsKatarina Ulfsdotter Gunnarsson, Martin Henriksson, Marcus BendtsenClinicoeconomics and Outcomes Research : CEOR|November 13, 2012
Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertensionOla Granström, Lars-Åke Levin, Martin HenrikssonJournal of Medical Internet Research|March 27, 2024
Digital Alcohol Interventions Could Be Part of the Societal Response to Harmful Consumption, but We Know Little About Their Long-Term Costs and Health OutcomesKatarina Ulfsdotter Gunnarsson, Martin Henriksson, Marcus BendtsenHealth and Quality of Life Outcomes|July 30, 2017
How is disease severity associated with quality of life in psoriasis patients? Evidence from a longitudinal population-based study in SwedenKirk Geale, Martin Henriksson, Marcus Schmitt-EgenolfMedicine, Health Care, and Philosophy|June 1, 2024
Is a larger patient benefit always better in healthcare priority setting?Lars Sandman, Jan Liliemark, Erik Gustavsson, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 29, 2025
Pharmaceutical Pricing Evidence From a Healthcare System With Multiple Cost-per-Quality-Adjusted Life-Year ThresholdsAnton P H Klockhoff, Jonathan Siverskog, Martin HenrikssonMedical Decision Making : an International Journal of the Society for Medical Decision Making|March 6, 2020
Subcategorizing the Expected Value of Perfect Implementation to Identify When and Where to Invest in Implementation InitiativesKasper Johannesen, Magnus Janzon, Tomas Jernberg, et al.Bioethics|October 27, 2020
Should we accept a higher cost per health improvement for orphan drugs? A review and analysis of egalitarian argumentsNiklas Juth, Martin Henriksson, Erik Gustavsson, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 10, 2021
Disease Progression Modeling for Economic Evaluation in Nonalcoholic Fatty Liver Disease-A Systematic ReviewLina Gruneau, Mattias Ekstedt, Stergios Kechagias, et al.Pageof 8